Stefan Schreiber, DDW 2021: Phase 2b/3 SELECTION and Long Term Extension Study Results
It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the Phase 2b/3 SELECTION and Phase 3 SELECTION long term extension study, investigating filgotinib for the treatment of ulcerative colitis.
The abstract entitled ‘133: SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTIONLTE LONG-TERM EXTENSION STUDY’ was presented at DDW 2021, May 21-23.
Questions:
- What is the rationale for the use of filgotinib in ulcerative colitis? (0:11)
- What did the SELECTION induction trials teach us about the efficacy and safety of filgotinib in patients with moderate to severely active ulcerative colitis? (1:25)
- Could you give us a brief overview of the aims and design of the maintenance study? (2:30)
- What were the results and conclusions of the study? (3:18)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, and Falk, outside the submitted DDW work.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of DDW 2021 (Virtual).
